+44 20 8123 2220
info@marketpublishers.com

KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031

https://marketpublishers.com/r/K63743D47FE3EN.html
Date: August 2023
Pages: 131
Price: US$ 4,799.00 (Single User License)
ID: K63743D47FE3EN

Abstracts

The NRAS, HRAS and KRAS market is expected to reach USD 73 million in 2021 and anticipated to grow at a CAGR of 53.6% during the forecast period 2021-2031

In 2020, an estimated 10 million reported fatalities were attributed to cancer, standing as a significant global cause of mortality. The predominant reason for this high mortality rate often stems from late detection, leading to delayed treatment and subsequently diminishing survival prospects. The COVID-19 pandemic further complicated the landscape of cancer care as healthcare facilities had to make the difficult decision to cancel visits to preserve resources and curb the spread of the virus. As a result, the National Cancer Institute has projected a potential 10,000 preventable deaths in the coming decade due to delays in cancer screening and treatment induced by the

+44 20 8123 2220
info@marketpublishers.com

pandemic. Globally, the reported cases of cancer in 2020 amounted to approximately 50.5 million, with breast and lung cancers prevailing as the most common types.

The pursuit of cancer therapeutics continues to be a paramount focus within the pharmaceutical industry, owing to the challenges associated with conventional treatments like chemotherapy and radiation therapy. Presently, developers are directing their efforts towards drugs that target specific oncogenic mutations driving disease progression. Notably, previously deemed 'undruggable' targets, such as RAS mutations present in 30% of human cancers, have garnered significant attention. These efforts culminated in the USFDA's approval of LUMAKRAS™ (sotorasib) in 2021 for treating metastatic non-small cell lung cancer in patients with KRAS G12C mutations. The efficacy and safety profile of this drug have ignited investigations into its potential application across various solid tumor indications, including colorectal cancer. Multiple entities, encompassing major pharmaceutical companies, are actively engaged in the development of therapies targeting RAS mutations due to the promising prospects, thereby attracting substantial interest from both private and public investors. With numerous candidates progressing to advanced development stages, a robust market expansion is anticipated within this domain.

Report Coverage

The report examines the KRAS market, focusing on target indication, molecule type, therapy type, administration route, and key geographical regions.

An analysis is conducted on factors impacting market growth, including drivers, restraints, opportunities, and challenges.

Evaluation of potential advantages and obstacles within the market is provided, along with insights into the competitive landscape for leading market players.

Revenue forecasts are made for market segments across five major regions.

A comprehensive overview of current therapies targeting RAS is presented, detailing their developmental status, molecule types, therapy approaches, targeted diseases, genes, treatment lines, and administration routes. Additionally, it includes information about companies involved in RAS targeting therapy development based on establishment year, employee count, and global presence.

+44 20 8123 2220
info@marketpublishers.com

An extensive analysis of completed, ongoing, and planned clinical trials focusing on RAS targeting therapies is included, evaluating parameters such as trial details, patient demographics, sponsors, objectives, indications, and geographical distribution.

Competitive analysis focuses on key players in the KRAS market, assessing their portfolio strength, company sizes, and lead molecule development stages.

Detailed profiles of major players in RAS targeting therapies are provided, encompassing company overview, product portfolio, recent advancements, and future outlook.

Analysis of over 1,600 peer-reviewed scientific articles published between January 2020 and April 2021 related to RAS targeting therapy research is conducted. This includes trends in publication years, focus areas, molecule types, keywords, and key journals based on article numbers and impact factors.

Recent partnerships established between stakeholders in RAS targeting therapy development from 2016 to 2021 are described, focusing on partnership models such as R&D agreements, licensing agreements, product development, and clinical trial agreements.

In-depth analysis of investments made in the KRAS market from 2016 to 2021, including venture capital financing, debt financing, grants/awards, IPOs, and subsequent offerings, is provided.

Detailed commercialization strategies employed by drug developers engaged in the KRAS market across different therapy development stages - before drug launch, during drug launch, and post-marketing stage - are examined.

Key Market Companies

Amgen

GlobeImmune

Jacobio Pharmaceuticals

+44 20 8123 2220
info@marketpublishers.com

Mirati Therapeutics

Novartis

Onconova Therapeutics

Targovax

Verastem Oncology

+44 20 8123 2220
info@marketpublishers.com

Contents

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of RAS Targeting Therapies
3.2. Approaches Used to Target Mutated RAS Gene
3.3. Historical Notable Developments
3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers

4. CURRENT MARKET LANDSCAPE

4.1. RAS Targeting Therapies: Pipeline Review
  4.1.1. Analysis by Phase of Development
  4.1.2. Analysis by Route of Administration
  4.1.3. Analysis by Line of Treatment
  4.1.4. Analysis by Type of Therapy
  4.1.5. Analysis by Type of Molecule
  4.1.6. Analysis by Target Gene
  4.1.7. Analysis by Target Therapeutic Area
  4.1.8. Analysis by Phase of Development and Leading Players
4.2. RAS Targeting Therapies: Developer Landscape
  4.2.1. Analysis by Year of Establishment
  4.2.2. Analysis by Company Size
  4.2.3. Analysis by Location of Headquarters
  4.2.4. Analysis by Geography

5. CLINICAL TRIALS AND ENDPOINT ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

5.1. RAS Targeting Therapies: List of Clinical Trials
5.1.1. Analysis by Trial Status
5.1.2. Analysis by Trial Registration Year
5.1.3. Analysis by Type of Masking
5.1.4. Analysis by Type of Intervention Model
5.1.5. Analysis by Study Design
5.1.6. Analysis by Type of Sponsor
5.1.7. Most Active Players: Analysis by Number of Trials Registered
5.1.8. Analysis by Trial Registration Year and Geography
5.1.9. Analysis by Type of Target Indication
5.1.10. Analysis by Enrolled Patient Population
5.1.11. Analysis of Enrolled Patient Population by Geography
5.1.12. Analysis of Number of Clinical Trials by Geography

6. PRODUCT COMPETITIVENESS ANALYSIS

6.1. Product Competitiveness: North America
6.2. Product Competitiveness: Europe
6.3. Product Competitiveness: Asia-Pacific

7. COMPANY PROFILES

7.1. Amgen
7.1.1. Company Overview
7.1.2. Financial Information
7.1.3. Portfolio of RAS Targeting Therapies
7.1.4. Recent Developments and Future Outlook
7.2. GlobeImmune
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Portfolio of RAS Targeting Therapies
7.2.4. Recent Developments and Future Outlook
7.3. Jacobio Pharmaceuticals
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Portfolio of RAS Targeting Therapies
7.3.4. Recent Developments and Future Outlook
7.4. Mirati Therapeutics
7.4.1. Company Overview

+44 20 8123 2220
info@marketpublishers.com

7.4.2. Financial Information
7.4.3. Portfolio of RAS Targeting Therapies
7.4.4. Recent Developments and Future Outlook
7.5. Novartis
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Portfolio of RAS Targeting Therapies
7.5.4. Recent Developments and Future Outlook
7.6. Onconova Therapeutics
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Portfolio of RAS Targeting Therapies
7.6.4. Recent Developments and Future Outlook
7.7. Targovax
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Portfolio of RAS Targeting Therapies
7.7.4. Recent Developments and Future Outlook
7.8. Verastem Oncology
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Portfolio of RAS Targeting Therapies
7.8.4. Recent Developments and Future Outlook

8. PUBLICATION ANALYSIS

8.1. RAS Targeting Therapies: Recent Publications
8.1.1. Analysis by Year of Publication
8.1.2. Analysis by Type of Publication
8.1.3. Analysis by Study Objective
8.1.4. Analysis by Emerging Focus Areas
8.1.5. Analysis by Target Therapeutic Area
8.1.6. Analysis by Target Gene
8.1.7. Analysis by Target Indication
8.1.8. Analysis by Affiliation of First Author
8.1.9. Leading Players: Analysis by Number of Publications
8.1.10. Key Journals: Analysis by Number of Publications

9. PARTNERHSIPS AND COLLABORATIONS

+44 20 8123 2220
info@marketpublishers.com

9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Type of Partner
9.1.4. Analysis by Type of Molecule
9.1.5. Most Active Players: Analysis by Number of Partnerships
9.1.6. Most Active Partners: Analysis by Number of Partnerships
9.1.7. Regional Analysis
9.1.8. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

10.1. RAS Targeting Therapies: Funding and Investments
10.1.1. Analysis by Number of Funding Instances
10.1.2. Analysis by Amount Invested
10.1.3. Analysis by Type of Funding
10.1.4. Most Active Players: Analysis by Amount Raised
10.1.5. Most Active Investors: Analysis by Number of Instances
10.1.6. Analysis by Geography

11. KEY COMMERCIALIZATION STRATEGIES

11.1. Successful Drug Launch Strategy: ROOTS Framework
11.2. Successful Drug Launch Strategy: Product Differentiation
11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
11.4.1. Strategies Adopted Before Therapy Approval
11.5. Strategies Adopted During / Post Therapy Approval
11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

12.1. Forecast Methodology and Key Assumptions
12.2. Global RAS Targeting Therapies Market, 2021-2031
12.3. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Target

+44 20 8123 2220
info@marketpublishers.com

Indication
12.4. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Molecule
12.5. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Type of Therapy
12.6. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Route of Administration
12.7. Global RAS Targeting Therapies Market, 2021-2031: Distribution by Geography
12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
12.8.1. LUMAKRASTM (Amgen): Sales Forecast
12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
12.8.3. AMO-01 (AMO Pharma): Sales Forecast
12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
12.8.5. Binimetinib (Array Biopharma): Sales Forecast
12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
12.8.7. LXH274 (Novartis): Sales Forecast
12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
12.8.10. TG01 (Targovax): Sales Forecast
12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
12.8.12. siG12D (Silenseed): Sales Forecast

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031

Product link: https://marketpublishers.com/r/K63743D47FE3EN.html

Price: US$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/K63743D47FE3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

+44 20 8123 2220
info@marketpublishers.com

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970